BRIEF-Nanjing Leads Biolabs Signs Exclusive Global License Agreement With Dianthus
Reuters
Oct 16
BRIEF-Nanjing Leads Biolabs Signs Exclusive Global License Agreement With Dianthus
Oct 16 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:
EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047
WILL RECEIVE UPFRONT AND POTENTIAL NEAR-TERM MILESTONE PAYMENTS UP TO $38 MILLION, UP TO $1 BILLION IN POTENTIAL CLINICAL DEVELOPMENT
Further company coverage: 9887.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.